| Q21284500 | A comprehensive review on metabolic syndrome |
| Q36577081 | A low-dose atorvastatin and losartan combination directly improves aortic ring relaxation and diminishes ischaemic-reperfusion injury in isolated rat hearts |
| Q42131252 | ADMA, SDMA and L-arginine may be Novel Targets in Pharmacotherapy for Complications due to Cardiopulmonary Bypass |
| Q36649671 | Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade |
| Q24309900 | Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation |
| Q40212788 | Angiotensin Receptor Blockade Modulates NFκB and STAT3 Signaling and Inhibits Glial Activation and Neuroinflammation Better than Angiotensin-Converting Enzyme Inhibition |
| Q43057341 | Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function |
| Q54573248 | Angiotensin-(1-7) decreases LPS-induced inflammatory response in macrophages. |
| Q28200344 | C-reactive protein (CRP)-lowering agents |
| Q33888096 | Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB |
| Q37883908 | Combination inhibition of the renin-angiotensin system: is more better? |
| Q25257883 | Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b |
| Q36985325 | Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors. |
| Q39255610 | Comprehensive evaluation of the effects of enalapril on matrix metalloproteinases levels in hypertension. |
| Q43820909 | Cuminum cyminum, a dietary spice, attenuates hypertension via endothelial nitric oxide synthase and NO pathway in renovascular hypertensive rats. |
| Q28196378 | Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril |
| Q50732895 | Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats. |
| Q36752124 | Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity? |
| Q42917973 | Effect of Amlodipine + Candesartan on Cardiovascular Events in Hypertensive Patients With Coronary Artery Disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study) |
| Q37295193 | Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the ramipril C-reactive pRotein randomized evaluation (4R) trial results |
| Q37209409 | Effect of erythropoietin-stimulating agent on uremic inflammation |
| Q42931550 | Effect of oral sirolimus therapy on inflammatory biomarkers following coronary stenting |
| Q37123175 | Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria |
| Q37672751 | Effects of valsartan on inflammatory and oxidative stress markers in hypertensive, hyperglycemic patients: an open-label, prospective study |
| Q30446535 | Evidence for benefits of angiotensin receptor blockade beyond blood pressure control |
| Q36902746 | Fat cell-derived modulators of vascular cell pathophysiology: the list keeps growing |
| Q45979858 | First-in-man use of polymer-free valsartan-eluting stents in small coronary vessels: a comparison to polymer-free rapamycin (2%)-eluting stents. |
| Q24242787 | Hypolipidemic and antihypertensive drugs for prevention of cardiovascular complications in patients with rheumatoid arthritis |
| Q39115238 | Immunologic Effects of the Renin-Angiotensin System |
| Q36674320 | Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress |
| Q36170046 | Inhibitory effects of telmisartan on culture and proliferation of and Kv1.3 potassium channel expression in peripheral blood CD4+ T lymphocytes from Xinjiang Kazakh patients with hypertension |
| Q37411117 | Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story |
| Q58585770 | Interactions between the Cyclooxygenase Metabolic Pathway and the Renin-Angiotensin-Aldosterone Systems: Their Effect on Cardiovascular Risk, from Theory to the Clinical Practice |
| Q90872650 | Interleukin-17 enhances cardiac ventricular remodeling via activating MAPK pathway in ischemic heart failure |
| Q38517201 | Interplay between proteins and metabolic syndrome-A review |
| Q41138356 | Irbesartan, an angiotensin II receptor antagonist, with selective PPAR-gamma-modulating activity improves function and structure of chemotherapy-damaged ovaries in rats. |
| Q36309624 | Is atrial fibrillation an inflammatory disorder? |
| Q48317107 | Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease |
| Q46368521 | Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects |
| Q37559372 | Matrix metalloproteinases and peripheral arterial disease |
| Q37160916 | Modification of the secretion pattern of proteases, inflammatory mediators, and extracellular matrix proteins by human aortic valve is key in severe aortic stenosis |
| Q51070174 | Modulation of the kallikrein/kinin system by the angiotensin-converting enzyme inhibitor alleviates experimental autoimmune encephalomyelitis. |
| Q37683209 | Novel Immune Mechanisms in Hypertension and Cardiovascular Risk. |
| Q37390750 | Optimal medical treatment of cardiovascular risk factors: can we prevent the development of heart failure? |
| Q36346487 | Pharmacological basis of different targets for the treatment of atherosclerosis. |
| Q58691749 | Preclinical and Clinical Effects of RAS Inhibition with a Focus on Telmisartan |
| Q44572156 | Predictor of event-free survival in patients with myocardial infarction |
| Q44952251 | Preoperative treatment with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker has no beneficial effect on the development of new-onset atrial fibrillation after off-pump coronary artery bypass graft surgery |
| Q36257966 | Protective effects of angiotensin II interruption: evidence for antiinflammatory actions |
| Q36737718 | Ramipril and Losartan Exert a Similar Long-Term Effect upon Markers of Heart Failure, Endogenous Fibrinolysis, and Platelet Aggregation in Survivors of ST-Elevation Myocardial Infarction: A Single Centre Randomized Trial. |
| Q46455257 | Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxidative stress and adhesion molecules in patients with persistent atrial fibrillation |
| Q57615279 | Recomendaciones específicas para el manejo del paciente con síndrome metabólico |
| Q36596821 | Reduction of C-reactive protein and the use of anti-hypertensives. |
| Q39705754 | Reduction of age-associated arterial wall changes by low-dose valsartan. |
| Q37209809 | Serum Concentrations of Endothelin-1 and Matrix Metalloproteinases-2, -9 in Pre-Hypertensive and Hypertensive Patients with Type 2 Diabetes |
| Q37151935 | Targeting cardiovascular protection: the concept of dual renin-angiotensin system control |
| Q37371365 | The chronic blockade of angiotensin I-converting enzyme eliminates the sex differences of serum cytokine levels of spontaneously hypertensive rats. |
| Q46210012 | The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes |
| Q37479070 | The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man |
| Q47818128 | The effects of telmisartan on the nuclear factor of activated T lymphocytes signalling pathway in hypertensive patients |
| Q37158159 | The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies |
| Q36815978 | Treating the metabolic syndrome. |
| Q38317550 | Update on the role of angiotensin in the pathophysiology of coronary atherothrombosis |
| Q34093100 | Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information |
| Q37975897 | Vascular effects of glycoprotein130 ligands--part II: biomarkers and therapeutic targets |
| Q47654610 | Venthamarai chooranam, a polyherbal Siddha medicine, alleviates hypertension via AT₁R and eNOS signaling pathway in 2K1C hypertensive rats. |
| Q82448451 | [Expression of angiotensin I converting enzyme in pulmonary hypertension] |
| Q82060808 | [Factors influencing plasma concentrations of C-reactive protein in patients with type 2 diabetes mellitus] |
| Q92366057 | hsCRP Level and the Risk of Death or Recurrent Cardiovascular Events in Patients With Myocardial Infarction: a Healthcare-Based Study |